ATP-competitive partial antagonists of the IRE1α RNase segregate outputs of the UPR

The unfolded protein response (UPR) homeostatically matches endoplasmic reticulum (ER) protein-folding capacity to cellular secretory needs. However, under high or chronic ER stress, the UPR triggers apoptosis. This cell fate dichotomy is promoted by differential activation of the ER transmembrane kinase/endoribonuclease (RNase) IRE1 alpha. We previously found that the RNase of IRE1 alpha can be either fully activated or inactivated by ATP-competitive kinase inhibitors. Here we developed kinase inhibitors, partial antagonists of IRE1 alpha RNase (PAIRs), that partially antagonize the IRE1 alpha RNase at full occupancy. Biochemical and structural studies show that PAIRs promote partial RNase antagonism by intermediately displacing the helix alpha C in the IRE1 alpha kinase domain. In insulin-producing beta-cells, PAIRs permit adaptive splicing of Xbp1 mRNA while quelling destructive ER mRNA endonucleolytic decay and apoptosis. By preserving Xbp1 mRNA splicing, PAIRs allow B cells to differentiate into immunoglobulin-producing plasma cells. Thus, an intermediate RNase-inhibitory 'sweet spot', achieved by PAIR-bound IRE1 alpha, captures a desirable conformation for drugging this master UPR sensor/effector.

Automated summary

The development of partial antagonists of IRE1 alpha RNase (PAIRs) allows for adaptive splicing of Xbp1 mRNA while suppressing destructive ER mRNA decay and apoptosis, capturing an intermediate RNase-inhibitory 'sweet spot' for drugging the UPR sensor/effector.